Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). (Q40239582)
Jump to navigation
Jump to search
scientific article published on 6 March 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). |
scientific article published on 6 March 2014 |
Statements
1 reference
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). (English)
1 reference
1 reference
John D Hainsworth
1 reference
Karim Fizazi
1 reference
Mary-Ellen Taplin
1 reference
Fred Saad
1 reference
Howard I Scher
1 reference
Tomasz M Beer
1 reference
Celestia S Higano
1 reference
Eric J Small
1 reference
Dana E Rathkopf
1 reference
Matthew R Smith
1 reference
Johann S de Bono
1 reference
Christopher J Logothetis
1 reference
Neal D Shore
1 reference
Paul de Souza
1 reference
Peter F A Mulders
1 reference
Paul Mainwaring
1 reference
Scott North
1 reference
Yves Fradet
1 reference
Hendrik Van Poppel
1 reference
Thomas W Flaig
1 reference
Eleni Efstathiou
1 reference
Evan Y Yu
1 reference
Thomas W Griffin
1 reference
Mary B Todd
1 reference
Margaret K Yu
1 reference
Youn C Park
1 reference
Thian Kheoh
1 reference
Arturo Molina
1 reference
Charles J Ryan
1 reference
6 March 2014
1 reference
1 reference
66
1 reference
5
1 reference
815-825
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference